- Home
- IMNN vs TLPH Comparison
IMNN vs TLPH Comparison
Compare IMNN & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- TLPH
- Stock Information
- Founded
- IMNN 1982
- TLPH 2005
- Country
- IMNN United States
- TLPH United States
- Employees
- IMNN N/A
- TLPH N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- TLPH Health Care
- Exchange
- IMNN Nasdaq
- TLPH Nasdaq
- Market Cap
- IMNN 12.1M
- TLPH 11.1M
- IPO Year
- IMNN 1985
- TLPH 2011
- Fundamental
- Price
- IMNN $5.04
- TLPH $0.94
- Analyst Decision
- IMNN Buy
- TLPH Strong Buy
- Analyst Count
- IMNN 2
- TLPH 1
- Target Price
- IMNN $182.61
- TLPH $6.00
- AVG Volume (30 Days)
- IMNN 55.1K
- TLPH 4.3M
- Earning Date
- IMNN 11-06-2025
- TLPH 11-12-2025
- Dividend Yield
- IMNN N/A
- TLPH N/A
- EPS Growth
- IMNN N/A
- TLPH N/A
- EPS
- IMNN N/A
- TLPH N/A
- Revenue
- IMNN N/A
- TLPH $27,000.00
- Revenue This Year
- IMNN N/A
- TLPH N/A
- Revenue Next Year
- IMNN N/A
- TLPH $14,533.26
- P/E Ratio
- IMNN N/A
- TLPH N/A
- Revenue Growth
- IMNN N/A
- TLPH N/A
- 52 Week Low
- IMNN $4.83
- TLPH $0.38
- 52 Week High
- IMNN $41.22
- TLPH $1.20
- Technical
- Relative Strength Index (RSI)
- IMNN 27.77
- TLPH 75.75
- Support Level
- IMNN $5.53
- TLPH $0.88
- Resistance Level
- IMNN $5.85
- TLPH $1.20
- Average True Range (ATR)
- IMNN 0.32
- TLPH 0.13
- MACD
- IMNN 0.02
- TLPH 0.03
- Stochastic Oscillator
- IMNN 4.57
- TLPH 62.70
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.